The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results